Extended Data Fig. 1: Study schema for enrolled patients in the dose-escalation or dose expansion (N=479).
NSCLC; non-small cell lung cancer; PD-1, programmed cell death protein 1; Q3W, every 3 weeks; R/R relapsed/refractory.
Extended Data Fig. 1: Study schema for enrolled patients in the dose-escalation or dose expansion (N=479). | Nature Medicine
